Finerenone Dose–Exposure–Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Pharmacokinetics"
DOI: 10.1007/s40262-021-01083-1
Abstract: Finerenone is a nonsteroidal selective mineralocorticoid receptor antagonist (MRA) that demonstrated efficacy in delaying the progression of chronic kidney disease (CKD) and reducing cardiovascular events in patients with CKD and type 2 diabetes mellitus in… read more here.
Keywords: potassium; response; finerenone dose; fidelio dkd ... See more keywords